Vicore Pharma Holding AB (publ) announced the addition of experienced executives to its management team, strengthening business and commercial operations as the company's research and development activities approach key commercial decision points. Åsa Magnusson will join as Vicore's Chief Commercial Officer and Jessica Shull, recently recruited Head of Digital Therapeutics will also join the Vicore management. Åsa Magnusson will take responsibility for the company's commercialization activities. She has more than 20 years of experience as a commercial executive in the pharmaceutical industry with focus on securing market access and launching rare disease medicines in areas with a high unmet medical need. She joins Vicore from Arvelle Therapeutics - a CNS and epilepsy focused biotech company based in Switzerland. Previously, Åsa worked in different international and Nordic commercial roles at Alexion, expanding innovative antibody products such as Soliris and Ultomiris. Before that, she headed the marketing of Actelion's pulmonary arterial hypertension (PAH) pharmaceuticals, including launching Opsumit and new indications for Tracleer in the Nordic territories. Åsa will take up her role with Vicore in October 2021. Jessica Shull joined Vicore in May 2021 to oversee the development and launch of the VP04 digital therapeutic program in IPF. Before joining Vicore, Jessica gained more than 20 years' experience in the field of digital technologies for healthcare including development of virtual surgical devices. She is considered an authority in HTA requirements for patient-facing software and innovation adoption in Europe and abroad.